Shares of Corcept Therapeutics surged 18.34% during after-hours trading on Wednesday, as investors reacted to the company's second-quarter financial results, which far exceeded market expectations.

The robust after-hours advance was fueled by Corcept's Q2 earnings release. The company reported earnings per share of $0.36, dramatically surpassing the analyst consensus estimate of $0.00. Revenue reached $256.147 million, a 31.74% increase from the same period last year and well above the Street estimate of $219.988 million. The outperformance was primarily driven by the continued commercial strength of its flagship product Korlym, the successful launch of newly approved Lifyorli, and encouraging pipeline progress, including the resubmission of its New Drug Application for Relacorilant for Cushing's syndrome.

These results reinforced investor confidence in Corcept's growth trajectory, triggering a sharp upward repricing in the stock during the extended session.